Comparative Pharmacology
Head-to-head clinical analysis: ALVAIZ versus CANTIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALVAIZ versus CANTIL.
ALVAIZ vs CANTIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alvai... (currently unavailable).
CANTIL (mepenzolate bromide) is a quaternary ammonium anticholinergic agent that blocks muscarinic acetylcholine receptors, reducing gastrointestinal motility and gastric acid secretion.
100 mg orally once daily with or without food.
50 mg orally three times daily, may increase to 100 mg three times daily if needed
None Documented
None Documented
Terminal elimination half-life is 12–15 hours in patients with normal renal function; prolonged to 24–40 hours in moderate to severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 10-12 hours; clinically, this supports twice-daily dosing in patients with normal renal function.
Approximately 70% of the dose is excreted renally as unchanged drug, 20% via biliary/fecal elimination, and 10% as oxidative metabolites in urine.
Primarily renal excretion of unchanged drug and metabolites; approximately 60-70% eliminated renally, with about 30-40% excreted in feces via biliary elimination.
Category C
Category C
Antispasmodic
Anticholinergic / Antispasmodic